Kweder: new law slows down FDA approvals

Share this article:
While it holds exciting promise for protecting public health, last year's FDA Amendments Act (FDAAA) is actually slowing down new drug approvals, a key agency official warned in June.

FDA Office of New Drugs Deputy director Sandra Kweder cautioned the Drug Information Association's annual meeting in Boston that this legislation is exceedingly complex and, at least in its initial application, is likely to result in delays by FDA in carrying out its individual provisions.

Under the FDAAA, Kweder said, “to assure conformance with provisions of Title IX, every NDA and BLA is a ‘first' so far as the agency is concerned,” she told the Drug Information Association annual meeting in Boston. “Everything we do must be justified, and every letter must be reviewed by the lawyers.”

She pointed out that every application must be considered on a case-by-case basis to determine which provisions apply, and which do not—for example, whether to require sponsors to produce a risk evaluation and mitigation strategy to accompany particular products.
Share this article:
close

Next Article in Features

Email Newsletters

More in Features

Antidote: On Cystic Fibrosis treatments

Antidote: On Cystic Fibrosis treatments

Recent treatments in CF, including the inhaled antibiotic Tobramycin, have increased lifespan well into adulthood.

The $3 generic and the $1,000 pill: pharma outsiders just don't get it

The $3 generic and the $1,000 pill: pharma ...

What do you call the people who treat medical breakthroughs as if they were bank heists? Malicious? Uninformed? Not with it?

Leadership Exchange Uncut : The Agency-Client Relationship

Leadership Exchange Uncut : The Agency-Client Relationship

Click the above link to access MM&M's first Leadership Exchange Uncut e-book, "The Agency-Client Relationship"